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Abstract 
The value of adding induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) for the treatment of 
locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. In our recent article entitled “Induction 
chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally 
advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial” published in the Lancet 
Oncology, we reported the results of a phase III, multicenter, randomized controlled trial comparing cisplatin, 5‑fluo‑
rouracil, and docetaxel (TPF) IC plus CCRT versus CCRT alone in patients with T3‑4N1/TxN2‑3M0 NPC (ClinicalTrials.gov 
registration number NCT01245959). The IC‑plus‑CCRT group showed significantly higher 3‑year failure‑free survival, 
overall survival, and distant failure‑free survival rates than the CCRT‑alone group, with an acceptable toxicity profile. 
Our study suggests that adding TPF IC to CCRT could increase survival rates and reduce distant failure in patients with 
locoregionally advanced NPC. However, long‑term follow‑up is required to assess the eventual efficacy and toxicity of 
this strategy, and a more accurate method to determine prognosis is needed to enable better tailoring of treatment 
strategy for individual patients.
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Background
Nasopharyngeal carcinoma (NPC) is a unique head and 
neck cancer with an extremely unbalanced endemic dis-
tribution [1, 2]. Radiotherapy is the primary treatment 
modality for non-disseminated NPC. With advances in 
imaging techniques, the advent of intensity-modulated 
radiotherapy (IMRT), and the use of concurrent chem-
otherapy in patients with advanced disease, the sur-
vival rates of patients with NPC have been substantially 
improved [3]. The 5-year overall survival (OS) rates are 
high for patients with stage I–II disease (90%–100%) but 
unsatisfactory for patients with stage III–IVB disease 
(60%–85%), with distant metastasis being the major pat-
tern of failure [4, 5].
To further improve systemic control and survival of 
patients with locoregionally advanced NPC, adding 
induction chemotherapy (IC) to concurrent chemora-
diotherapy (CCRT) seems to be a promising treatment 
strategy. NPC is highly responsive to IC, and the advan-
tages of IC include better tolerability, early eradication 
of micrometastases, and simultaneous normal tissue 
protection and increased tumor radiosensitivity due 
to tumor shrinkage. However, the value of adding IC to 
CCRT remains controversial in the treatment of locore-
gionally advanced NPC [6–8]. In a randomized phase II 
study by Hui et al. [6], IC with docetaxel and cisplatin fol-
lowed by CCRT resulted in a 3-year OS benefit compared 
with CCRT alone in patients with stage III–IVB NPC; 
however, in another phase II trial, by Fountzilas et al. [7], 
IC using cisplatin, epirubicin, and paclitaxel followed by 
CCRT did not significantly increase OS or progression-
free survival rate compared with CCRT alone. Tan et al. 
[8] performed a randomized phase II/III trial that com-
pared IC (gemcitabine, carboplatin, and paclitaxel) plus 
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CCRT with CCRT alone in patients with stage III-IVB 
NPC and observed no significant survival differences 
between the two groups. Different trial designs and study 
populations make direct comparisons of these studies 
difficult. In three Bayesian network meta-analyses, IC 
plus CCRT did not significantly increase OS compared 
with CCRT alone [9–11] but showed a significant benefit 
for distant control [10, 11]. The efficacy of IC followed by 
CCRT in locoregionally advanced NPC still lacks solid 
evidence from large-scale randomized controlled trials.
Main text
In our recent article entitled “Induction chemotherapy 
plus concurrent chemoradiotherapy versus concurrent 
chemoradiotherapy alone in locoregionally advanced 
nasopharyngeal carcinoma: a phase 3, multicentre, ran-
domised controlled trial” published in the Lancet Oncol-
ogy, we reported the results of a phase III, multicenter, 
randomized controlled trial at 10 institutions in China, 
which compared cisplatin, 5-fluorouracil, and docetaxel 
(TPF) IC plus CCRT vs CCRT alone in the treatment of 
locoregionally advanced NPC (ClinicalTrials.gov reg-
istration number NCT01245959) [12]. In this study, 
480 NPC patients with stage III–IVB (except T3–4N0; 
according to the 7th version of staging system of Union 
for International Cancer Control and American Joint 
Committee on Cancer) disease were randomly assigned 
to receive IC plus CCRT (n  =  241) or CCRT alone 
(n  =  239). Both groups received 100  mg/m2 cisplatin 
every 3 weeks for three cycles concurrently with IMRT. 
The IC-plus-CCRT group received docetaxel (60  mg/
m2 on d1), cisplatin (60 mg/m2 on d1), and 5-fluoroura-
cil (600  mg/m2 per day on d1–5, 120-h infusion) every 
3 weeks for three cycles before CCRT. The primary end-
point was failure-free survival rate. After a median fol-
low-up of 45 months, the IC-plus-CCRT group showed 
a significantly higher 3-year failure-free survival rate 
(80 vs. 72%; hazard ratio [HR]  =  0.68, 95% confidence 
interval [CI]: 0.48–0.97; P = 0.034), OS rate (92 vs. 86%; 
HR =  0.59, 95% CI: 0.36–0.95; P =  0.029), and distant 
failure-free survival rate (90 vs. 83%; HR  =  0.59, 95% 
CI: 0.37–0.96; P =  0.031) than the CCRT-alone group. 
No significant difference was observed in 3-year locore-
gional failure-free survival rates between the two groups 
(92 vs. 89%, P  =  0.117). During the entire treatment 
course, the IC-plus-CCRT group had significantly higher 
occurrence rate of grade 3 or 4 adverse events than 
the CCRT-alone group (73 vs. 54%, P  <  0.001), but the 
adverse events were generally uncomplicated and man-
ageable. We theorized that the effective TPF induction 
regimen, adequately powered sample size, and inclusion 
of patients with high-risk T3-4N1/TxN2-3M0 disease 
may have contributed to the positive results.
Our study showed that adding TPF IC to CCRT could 
significantly increase failure-free survival, OS, and dis-
tant failure-free survival rates in patients with locore-
gionally advanced NPC. Several randomized trials (such 
as NCT00201396, NCT00705627, and NCT01872962) 
are also evaluating the therapeutic benefits of adding 
different induction regimens to CCRT; we await con-
firmation of the value of this strategy. Moreover, our 
study showed that patients with T3-4N1/TxN2-3M0 
NPC could benefit from TPF IC; however, exploratory 
analysis for covariate interaction (e.g., N1 vs. N2-3) of 
the treatment effect did not find any significant interac-
tion, indicating that the effect of IC did not vary among 
the subgroups of patients with NPC [12]. Therefore, 
additional meta-analyses combining more relevant tri-
als are needed to determine whether certain subgroups 
of patients with NPC could benefit more from addi-
tional IC. In the study by Chua et al. [13], patients with 
detectable pre-treatment Epstein-Barr virus (EBV) DNA 
levels appeared to benefit from IC, which indicates that 
the pre-treatment EBV DNA level potentially has a role 
as a predictive marker for IC in stratifying patients with 
locoregionally advanced NPC.
Our study showed that IC plus CCRT was better than 
CCRT alone in the treatment of patients with locoregion-
ally advanced NPC; however, whether the induction-con-
current strategy is better than the concurrent-adjuvant 
sequence remains unclear. In the phase III trial NPC-
0501, Lee et  al. [14] evaluated the potential therapeutic 
benefit of changing from a concurrent-adjuvant chemo-
therapy sequence to an induction-concurrent chemo-
therapy sequence. Unadjusted comparisons of induction 
sequences versus adjuvant sequences did not reach sta-
tistical significance, but adjusted comparisons indicated 
favorable improvements by induction sequence [14]. In 
addition, whether an induction-concurrent sequence is 
sufficient for patients at high risk of distant failure still 
needs further evaluation. In our study, 14% of patients 
with N2-3 disease in the TPF IC-plus-CCRT group still 
experienced distant metastasis. Wang et al. [15] showed 
that NPC patients with persistently detectable plasma 
EBV DNA after curative radiotherapy have a higher rate 
of treatment failure and short survival, and administra-
tion of adjuvant chemotherapy in these patients could 
significantly reduce distant failure, suggesting that indi-
vidualized treatment based on EBV DNA is important 
to further improve the survival of patients at high risk of 
distant failure.
Some issues still need to be addressed regarding the use 
of IC in the treatment of NPC. First, it remains uncertain 
whether TPF is the best regimen to be recommended. 
Recently, Zhang et al. [16] showed that, in patients with 
recurrent or metastatic NPC, gemcitabine plus cisplatin 
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(GP) significantly extended progression-free survival and 
OS compared with 5-fluorouracil plus cisplatin. GP is 
also an effective and promising regimen for NPC; thus, 
we conducted another phase III, randomized trial com-
paring GP IC plus CCRT versus CCRT alone in patients 
with locoregionally advanced NPC (NCT01872962), and 
the currently observed benefit of TPF IC might also be 
achieved by using GP IC. Second, the prognostic value 
of tumor response to IC needs further evaluation. In our 
study, 9% of patients had stable disease after three cycles 
of TPF IC. Liu et  al. [17] found that an unsatisfactory 
tumor response (stable disease or disease progression) 
or detectable EBV DNA levels after IC were predic-
tors of poor prognosis for patients with locoregionally 
advanced NPC. In a prospective study of children and 
young adults with NPC, the radiation dose during CCRT 
was decreased to 54  Gy in patients who achieved com-
plete remission and 59.4 Gy in those who achieved partial 
remission after three cycles of IC; after a median follow-
up of 30  months, none of these patients experienced 
locoregional recurrence [18]. These findings warrant fur-
ther risk stratification and early treatment modification 
after IC in patients with locoregionally advanced NPC.
Conclusions
The results of our recent phase III trial showed that, for 
the treatment of locoregionally advanced NPC, the addi-
tion of TPF IC to CCRT significantly increased failure-free 
survival, OS, and distant failure-free survival rates. We 
recommend TPF IC followed by CCRT for the treatment 
of patients with locoregionally advanced NPC. However, 
long-term follow-up is required to assess the eventual 
efficacy and toxicity of this strategy, and a more accurate 
method to determine prognosis is needed to enable better 
tailoring of treatment strategy for individual patients.
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